Methods:
Participants with active TB, latent TB and non-tuberculous mycobacterial (NTM) infection were recruited into the “Assessing Antibiotic-Induced Liver Injury for the Stratification of Tuberculosis Patients” (ALISTER) clinical study at the Royal Infirmary, Edinburgh (ClinicalTrials.gov Identifier: NCT03211208). Participants with HIV-TB coinfection were recruited into the “Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy” (SAEFRIF) clinical trial at the Infectious Disease Institute, Kampala, Uganda (ClinicalTrials.gov Identifier: NCT03982277).